RESUMEN
Lippia sidoides Cham (Verbenaceae) is largely distributed in the northeastern region of Brazil. It is popularly known as 'Alecrim-pimenta'. Recent studies have shown that some species of Lippia have interesting pharmacological activities. This study aimed to evaluate the effect of a nanostructured thymol gel (TG) 1.2 mg/g on acute phase of ligature-induced periodontitis model [acute periodontal disease (APD)] in rats. APD was induced in 24 Wistar rats subjected to ligature placement on left molars in maxillae. Animals were treated with TG, immediately after APD induction. Saline-based gel was utilized as negative control and diethylammonium diclofenac gel 10 mg/g was used as positive control. Animals were randomly assigned into the groups. The periodontium and the surrounding gingiva were examined at histopathology, as well as the neutrophil influx into the gingiva was assayed using myeloperoxidase activity levels by ELISA method. TG treatment reduced tissue lesion at histopathology coupled to decreased myeloperoxidase activity production in gingival tissue when compared with the saline gel control group (p < 0.05). The TG gel was able to provide a significant myeloperoxidase decreasing in gingiva tissue confirming to be effective in reducing gingival inflammation in this model.
Asunto(s)
Lippia/química , Nanotecnología , Periodontitis/tratamiento farmacológico , Fitoterapia , Timol/farmacología , Animales , Brasil , Modelos Animales de Enfermedad , Cromatografía de Gases y Espectrometría de Masas , Geles/farmacología , Encía/metabolismo , Encía/patología , Masculino , Neutrófilos/citología , Aceites Volátiles/química , Peroxidasa/metabolismo , Hojas de la Planta/química , Aceites de Plantas/química , Ratas , Ratas WistarRESUMEN
OBJECTIVE: To investigate the efficacy of a transdermal nanoemulsion testosterone associated with transdermal estrogen therapy as a novel protocol treatment for emergent loss of libido. METHODS: Twenty-four women, aged 31-75 years (mean age, 51.7), with emergent loss of libido were allocated to treatment with a novel transdermal formulation of 500 µg/day of testosterone (Biolipid/B2®-testosterone) for 12 weeks, as part of an open label prospective study on peri- and post-menopausal women. Subjects applied the formulation on the right forearm. Clinical and laboratorial parameters including the sexual complaints; serum concentrations of testosterone, insulin, C-reactive protein, weight, blood pressure; body mass index and waist circumference were compared between baseline and 12 weeks after treatment. RESULTS: The mean total serum testosterone increased significantly (p = 0.009) after 12 weeks of treatment. No adverse or androgenic events were observed. There were positive and significant differences (p < 0.05) on sexual complaints, blood pressure, body mass index and waist circumference after transdermal nanoemulsion testosterone treatment. CONCLUSION: This protocol is effective in increasing testosterone levels in peri- and postmenopausal women with low libido.
OBJETIVO: Investigar a eficácia de uma nanoemulsão transdérmica de testosterona associada à terapia com estrogênio transdérmico como tratamento para a perda emergente da libido. MÉTODOS: Vinte e quatro mulheres, com idade entre 31-75 anos (idade média de 51,7), com perda emergente de libido foram incluídas num protocolo para tratamento de libido reduzida com uma formulação transdérmica de 500 µg/dia de testosterona (biolípido/B2®-testosterona) com 12 semanas de duração, como parte de um estudo prospectivo aberto em mulheres peri- e pós-menopausa. As participantes aplicaram a formulação no antebraço direito. Os parâmetros clínicos e laboratoriais, incluindo as queixas sexuais foram comparados entre os valores iniciais e 12 semanas após o tratamento. Mediram-se as concentrações séricas de testosterona, insulina, proteína C-reactiva, o peso, a pressão arterial; o índice de massa corporal e a circunferência da cintura. RESULTADOS: A média de testosterona total no soro aumentou significativamente (p = 0,009) após 12 semanas de tratamento. Não foram observados efeitos adversos ou androgênicos. Registraram-se reduções significativas (p < 0,05) sobre as queixas sexuais, da pressão arterial, do índice de massa corporal e da circunferência da cintura após o tratamento transdérmico com nanoemulsão de testosterona. CONCLUSÃO: O protocolo mostrou eficacia em aumentar os níveis de testosterona em e melhorar a libido em mulheres peri e pós-menopausa com baixa libido.